Literature DB >> 29550094

Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors.

Hidenobu Murafuji1, Hiroki Sakai2, Megumi Goto2, Yoshiaki Oyama2, Seiichi Imajo2, Hajime Sugawara2, Toshiyuki Tomoo2, Tsuyoshi Muto3.   

Abstract

A novel series of 1,3,6-trisubstituted 1,4-diazepan-7-ones were investigated as human kallikrein 7 (KLK7, stratum corneum chymotryptic enzyme) inhibitors. Based on the X-ray co-crystal structure of compound 1 bound to human KLK7, the derivatives of this scaffold were designed, synthesized, and evaluated. Through structure-activity relationship studies focused on the side chain located in the prime site region of the enzyme, representative compounds 15, 33a, and 35a were identified as highly potent and selective inhibitors of human KLK7.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,4-Diazepan-7-one; Atopic dermatitis; Kallikrein 7 inhibitor; Serine protease; Structure-based drug design

Mesh:

Substances:

Year:  2018        PMID: 29550094     DOI: 10.1016/j.bmcl.2018.03.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

Review 1.  Human Tissue Kallikreins-Related Peptidases Are Targets for the Treatment of Skin Desquamation Diseases.

Authors:  Marcelo B Zani; Aquiles M Sant'Ana; Rafael C Tognato; Jair R Chagas; Luciano Puzer
Journal:  Front Med (Lausanne)       Date:  2022-03-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.